The results showed clonal selection of loss-of-function mutations in JAK1 and JAK2 in two patients, which led to lack of response to interferon gamma, and a truncating mutation in the antigen-presenting protein B2M in another case, resulting in decreased immune cell recognition of tumor cells (61). This evidence concerns the gene IFNG and neoplasm.